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Abstract
Because illicit drugs are now widely consumed, every doctor
needs to know their acute medical consequences and complica-
tions. Here, we review the problems associated with the different
drugs from a systems-based viewpoint. Apart from the respiratory
depressant effect of opioids, crack cocaine is the most common
cause of respiratory complications, mainly linked with its mode of
use, with airway burns, pneumothorax, pneumomediastinum, and
lung syndromes being well-recognised sequelae. Because of its
marked cardiovascular effects, cocaine is also a major cause of
coronary syndromes and myocardial infarction. Amphetamines may
produce similar effects less commonly. Hyperthermia may occur
with cocaine toxicity or with 3,4-methylenedioxymethamphetamine
(MDMA) due to exertion or from serotonin syndrome. Cerebral
haemorrhage may result from the use of amphetamines or cocaine.
Hallucinations may follow consumption of LSD, amphetamines, or
cocaine. MDMA is a major cause of acute severe hyponatraemia
and also has been linked with hepatic syndromes. Collapse,
convulsions, or coma may be caused in different circumstances by
opioids, MDMA, or gamma hydroxybutyrate and may be aggravated
by other sedatives, especially alcohol and benzodiazepines.
Recognition of these acute complications is urgent, and treatment
must be based on an understanding of the likely underlying
problem as well as on basic principles of supportive care.
Introduction
Many substances are now widely taken for their mind-altering
properties. Their sought-after effects may be outweighed in
many cases by the dependence produced and, in a small
number of cases, by the medical complications that they may
cause. These complications do not often present a critical
threat to health, but when they do, the clinical diagnosis is
important and management often needs to be urgent and
decisive. The emergency may present outside the hospital, in
the emergency department, or in the intensive therapy unit,
and the diagnostic and therapeutic approach to the clinical
problem must be appropriate to each situation. Because the
general properties of the different substances are well known
and because polysubstance misuse is now very common, we
are adopting a systems-oriented approach to the main acute
complications of the currently available illicit substances (see
Table 1 for summary).
Respiratory complications
The illicit substance most commonly associated with respira-
tory complications requiring hospital admission is crack
cocaine. Smoking of crack cocaine (which vaporises at
187°C) can lead to thermal injury of the pharynx and airways,
which may be severe [1]. However, cough, haemoptysis,
pneumothorax, pneumomediastinum, pneumopericardium,
and haemothorax are the main acute complications of inhaling
crack cocaine vapour. Users commonly inhale deeply and
then perform a Valsalva manoeuvre to accentuate the absorp-
tion and effects of the drug. It is likely that this rise in intra-
alveolar pressure in addition to barotrauma caused by vigor-
ous coughing causes alveolar rupture and the dissection of
air in the peribronchiolar connective tissue. Similar complica-
tions are seen less commonly in cannabis smokers who also
inhale deeply and retain the smoke to facilitate absorption of
tetrahydrocannabinol, or THC. Both cocaine [2] and cannabis
[3] smoking as well as intravenous methylphenidate abuse [4]
have been associated with severe bullous emphysema, one
complication of which is pneumothorax. Management of
these complications follows conventional lines.
The principal subacute pulmonary complications of cocaine
use include pulmonary oedema, ‘crack lung’, interstitial
pneumonitis, and bronchiolitis obliterans with organising
pneumonia (BOOP). The diagnosis of cocaine-associated
pulmonary oedema may be delayed as clinicians may be
misled by the young age of the patient. Treatment with
diuretics, nitrates, and oxygen followed by mechanical
ventilation, if necessary, usually produces rapid improvement.
The pathogenesis of this condition is unclear, but the
negative inotropic effect of cocaine, which is often marked at
high doses, may be an important factor [5]. Crack lung is the
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Table 1
Summary of major complications following illicit drug use
Presentation Substances implicated Mechanism Specific treatment
Respiratory compromise Pneumothorax,  Cocaine, cannabis Barotrauma  Chest drainage
haemothorax
‘Crack lung’ Cocaine Interstitial and alveolar  Systemic corticosteroid 
inflammatory infiltration  administration
Pulmonary oedema Cocaine Oxygen, diuretics, nitrates
Interstitial pneumonitis,  Cocaine Ventilation where 
BOOP necessary
Chest pain/cardiovascular collapse Pneumomediastinum,  Cocaine, cannabis Barotrauma  Drainage where 
pneumopericardium necessary
Acute coronary  Cocaine Alpha-adrenergic  Sublingual nitrates, 
syndrome vasoconstriction, benzodiazepines 
platelet aggregation
Arrhythmias and  Cocaine Sodium channel 
sudden death blockade
Amphetamines Sympathetic 
hyperstimulation 
Cannabis
Confusion, convulsions,  With respiratory  Opioids, benzodiazepines, Central sedation Airway protection, 
collapse, coma depression ethanol, GHB  ventilation
With hyponaturaemia MDMA Cerebral oedema  Fluid restriction, 
(excess fluid consumption  hypertonic saline 
and ADH release) administration
Predominantly seizure  Cocaine,  Central nervous system  Benzodiazepines
activity amphetamines stimulation
Opioids, GHB,  Withdrawal
benzodiazepines, ethanol
Hyperthermia With agitated and  Cocaine (excited  Benzodiazepines, fluid 
paranoid behaviour,  delirium) resuscitation
collapse, and death
In extremis without  MDMA (exertional  Exertion, dehydration,  Active cooling ± 
rigidity hyperpyrexia) arousal, environmental  dantrolene
warming, alterations 
in skeletal muscle 
excitation-contraction 
coupling
With rigidity MDMA (serotonin  Contraction of  Paralysis
syndrome) antagonistic muscle 
groups 
Rhabdomyolysis With coma Opioids, benzodiazepines, Pressure necrosis Fluid administration, 
ethanol, GHB monitor for acute renal 
failure
With excessive muscle  MDMA Diffuse tissue disruption
contraction
Traumatic Any Impaired judgement, 
risk-taking behaviours
ADH, antidiuretic hormone; BOOP, bronchiolitis obliterans with organising pneumonia; GHB, gamma hydroxybutyrate; MDMA, 3,4-
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term given to acute dyspnoea and hypoxaemia, together with
(in more severe cases) fever, haemoptysis, and respiratory
failure in crack cocaine users [6]. Lung biopsy reveals diffuse
alveolar damage, alveolar haemorrhage, and interstitial and
intra-alveolar inflammatory cell infiltration which is eosinophilic
in severe cases. These improve promptly with systemic
corticosteroid administration, whereas milder cases usually
resolve spontaneously within 36 hours. In rare cases, crack
users may develop adult respiratory distress syndrome and
end-stage respiratory failure due to crack-associated inter-
stitial pneumonitis and BOOP. Use of cocaine or heroin by
inhalation can also lead to severe asthma [7].
Respiratory depression with bradypnoea and hypoxaemia
caused by diamorphine overdose is well known and readily
recognised by most clinicians. Similarly, the management is
straightforward, first ensuring a patent airway and adminis-
tering oxygen followed by naloxone or continued respiratory
support. It is important to remember that the half-life of
naloxone is shorter than that of most commonly abused
opioids and thus readministration may be necessary.
Respiratory depression and hypostatic pneumonia may occur
in gamma hydroxybutyrate (GHB) intoxication. There is no
effective antidote, so these patients may require intubation
and mechanical ventilation. However, rapid recovery is
common, and the patient may improve as preparations for
further care are being made.
Cardiovascular complications
Cocaine is the most common cause of chest pain in young
adults presenting to emergency departments and, in the
United States, is the cause of 25% of myocardial infarctions
(MIs) in people under 45 years of age [8]. The alpha-
adrenergic effect produced by the blockade of norepinephrine
reuptake causes coronary vasoconstriction, as has been
demonstrated with coronary angiography [9,10]. Additionally,
cocaine promotes platelet aggregation and in situ thrombus
formation and, in the longer term, accelerates atherosclerosis
and produces left ventricular hypertrophy [11]. Widespread
vasoconstriction causes increased myocardial oxygen
demand, and with cocaine’s sympathomimetic activity causing
tachycardia and hypertension, myocardial ischaemia and
infarction may occur; the risk of MI in patients with cocaine-
induced chest pain is approximately 6%. The usual clinical
presentation is of an acute coronary syndrome in a young
individual often without risk factors for ischaemic heart
disease. Electrocardiogram (ECG) interpretation in these
instances is extremely difficult and often ineffective in
excluding or confirming MI. Forty-three percent of cocaine-
using patients without infarction meet ECG criteria for
thrombolysis. Cardiac troponins are much more reliable in
this respect [12]. Consequently, most patients with clinical
findings suggestive of cocaine-associated chest pain are
admitted to the hospital. Creatine kinase (CK) and myocardial
CK may well be elevated in the absence of MI, due to increased
motor activity, hyperthermia, and skeletal-muscle injury.
Management is with oxygen, aspirin (unless at risk of
subarachnoid haemorrhage), benzodiazepines, and sub-
lingual nitrates. The benefit of coadministration of sublingual
nitrates and benzodiazepines has been a topic of recent
investigation. Baumann and colleagues [13] were unable to
find evidence of benefit in the coadministration of glyceryl
trinitrate (GTN) with diazepam over monotherapy in terms of
chest pain resolution and cardiac performance, perhaps due
to a lack of statistical power. Honderick and colleagues [14]
demonstrated an advantage in dual therapy (GTN and
lorazepam) over monotherapy (GTN), although the lack of a
placebo control and the failure to analyse by intention to treat
reduce the clinical applicability of these findings. Moreover,
the clinical reality is that these patients are prone to seizures
due to their cocaine usage, which provides a compelling
rationale for the urgent prophylactic use of benzodiazepines
in these situations. Most clinicians would agree that benzo-
diazepines should be given to all patients with cocaine-induced
chest pain who are anxious, tachycardic, or hypertensive.
In contrast, a clear consensus exists against the use of beta-
blockers, which have been shown to potentiate cocaine-
induced chest pain via unopposed alpha-adrenergic stimu-
lation [15,16]. Given the difficulty in definitively diagnosing
cocaine-induced MI, thrombolysis is rarely resorted to. The
infarction is often due to coronary spasm rather than
thrombosis, with evident implications for management; the
mortality for cocaine-induced MI is extremely low in patients
who reach the hospital alive.
Cocaine has also been associated with hypotension, cardiac
arrhythmias, and sudden death due to sodium channel
blockade if taken in large quantities. Other substances asso-
ciated with cardiac arrhythmias and sudden death include
3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’),
amphetamines, and cannabis, thought to be linked to
sympathetic hyperstimulation in the case of MDMA and
amphetamines. In many young victims of sudden death, it is
possible that death may be due to undiagnosed conduction
defects precipitated by illicit substance consumption. MDMA,
however, has a clear association with QT prolongation.
Methadone, often sold on the illicit market, is an important
cause of long QT syndrome and torsades de pointes [17].
Neurological complications
Deep coma may result from the consumption of illicit drugs,
particularly opioids or GHB, often in combination with alcohol
or benzodiazepines. GHB is a GABA analogue (as are its
precursors, gamma butyrolactone and 1,4-butanediol) whose
peak effects occur at approximately 30 to 45 minutes after
oral consumption and last for up to approximately 2.5 hours.
Volatile substance abuse may also result in coma. Respiratory
depression, aspiration of vomit, positional asphyxia, non-
traumatic rhabdomyolysis, and other complications may follow
depending on the depth and duration of central nervous
system depression. Management is supportive; naloxone may
Available online http://ccforum.com/content/12/1/202be used if opioid toxicity is apparent or suspected. Because
of the risk of provoking convulsions, flumazenil is not
recommended for reversal of benzodiazepine toxicity, and
physostigmine does not have a recommended role in
reversing GHB toxicity. Although ketamine is an anaesthetic
agent, toxicity rarely causes coma. More likely are euphoria,
numbness, ‘out of body’ sensations, confusion, disorientation,
and panic attacks.
Seizures may be caused by cocaine, amphetamines
(including MDMA), withdrawal states (opioids, GHB, benzo-
diazepines, and ethanol), and cerebral hypoxia. Though often
short-lived, they need to be controlled by benzodiazepines in
the first instance. Hallucinations can follow consumption of
LSD, psilocybe mushrooms, amphetamines, or cocaine. With
cocaine, hallucinations may be a relatively isolated unwanted
effect or may be part of cocaine-excited delirium. They also
occur in withdrawal states, most notably that of alcohol, but
also of benzodiazepines, GHB, and opioids.
A number of deaths from acute hyponatraemia have been
reported in association with MDMA abuse. The basic
mechanism is straightforward: MDMA causes excess anti-
diuretic hormone (ADH) production and thus a reduced renal
response to water loading, so that excess fluid ingestion
following MDMA leads to dilutional hyponatraemia and
cerebral oedema [18]. The most common presentation is
neurological, with confusion, delirium, convulsions, or coma.
More severe cerebral oedema may cause cerebral hypoxia
and uncal herniation. Pulmonary oedema may also occur. The
most important aspect of management is fluid restriction.
Most patients will produce a diuresis within hours as levels of
MDMA fall and ADH production resumes. However, in a
minority of severely ill patients, hypertonic saline may be
required. It should be noted that the chances of osmotic
demyelination syndrome on sodium repletion are extremely
remote in MDMA-associated hyponatraemia because the
derangement is acute in nature.
Stimulant drugs such as cocaine and amphetamines have
been associated with cerebrovascular events [19,20]. Both
have now been demonstrated in epidemiological studies; the
likelihood of haemorrhagic stroke is more common with
amphetamines, whereas thrombotic stroke is more common
with cocaine. Subarachnoid haemorrhage is likely to be more
severe and to have a worse outcome when cocaine is
implicated [21]. Spongiform leukoencephalopathy is an
unusual complication of illicit drug misuse with severe, often
fatal, neurological deterioration and lesions of the white
matter of the cerebrum, cerebellum, and basal ganglia, most
often precipitated by inhalation of vaporised heroin [22].
Hyperthermic complications
Excessive cocaine use can result in hallucinations, agitation,
and hyperthermia, and management is urgent. In addition,
cocaine-excited delirium, an important but unusual complica-
tion of cocaine use and considered to be an entity separate
from cocaine toxicity, is characterised by hyperthermia with
profuse sweating, followed by agitated and paranoid
behaviour (with dilated pupils); these extreme behavioural
disturbances may progress to collapse (often accompanied
by respiratory arrest) and death (cardiorespiratory arrest). It
occurs in regular cocaine users who have used the drug in
the previous 24 hours. Risk factors identified for fatal
cocaine-excited delirium include Afro-Caribbean race, male
gender, and administration of cocaine by smoking or injection
[23]. Warm summer weather also appears to be a precipitant
[24]. Despite the serious clinical problem and the risk of
death in police custody prior to admission, there are no clear
guidelines on the management of this condition, perhaps due
to its infrequent occurrence. Diazepam or lorazepam is known
to be effective in reducing neuronal excitation and its
consequences and in acting as a chemical restraint in the
interests of public safety. Urgent fluid resuscitation is also
likely to be of importance given the presence of hyperpyrexia.
The place of dopamine antagonists has not been established.
The hyperthermic complications of MDMA use are well
known. They can broadly be divided into two syndromes,
exertional hyperpyrexia and serotonin syndrome, although the
two may overlap. In exertional hyperpyrexia, it is clear that the
circumstances in which the drug is taken are important in the
development of this complication as implied by its frequent
occurrence in club-goers following prolonged dancing
[25,26]. This hypothesis is supported by animal studies
demonstrating increased hyperthermic response to MDMA in
warm crowded environments [27]. Patients may present in
extremis, collapsed, hypotensive, and tachycardic, with
hyperpyrexia without rigidity. Rhabdomyolysis may or may not
be present. Rapid deterioration may ensue, with impairment
of consciousness, disseminated intravascular coagulation,
and multi-organ failure (frequently five-organ failure). When
present, rhabdomyolysis is often marked, with peak serum CK
levels of 30,000 to 100,000 U/L. Prognosis correlates with
peak core temperature, with few survivors presenting with
temperatures in excess of 42°C (the highest temperature
recorded in a survivor was 42.9°C) [28]. Given the potentially
fatal nature of this condition, it is essential that the diagnosis
be made rapidly and appropriate management instituted
immediately. This consists essentially in fluid replacement to
support cardiac output and facilitate thermoregulation, rapid
cooling, and support for failing organ systems, often including
intubation, ventilation, and invasive monitoring.
The effect of hyperthermia on skeletal muscle is to reduce the
calcium requirement for excitation-contraction coupling and
thus establish a vicious cycle of heat production secondary to
muscle contraction. This is the rationale behind using
dantrolene to aid cooling of these patients, although its
benefit is uncertain. There has been no comparative study of
dantrolene in acute drug-induced hyperthermia, although it
has been studied in environmental heatstroke. In a
Critical Care    Vol 12 No 1 Devlin and Henry
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patients, dantrolene did not affect the rate of cooling [29]. A
recent review of case reports divided cases into groups
based on peak temperature. What emerged was that, in
patients whose peak temperature was 40.0°C to 41.9°C,
there were 10/10 survivors in the dantrolene-treated group
and 6/10 survivors in the non-dantrolene-treated group [30].
Patients with temperatures above 42°C tended to die
irrespective of treatment, whereas those with peak tempera-
tures below 40°C rarely developed rhabdomyolysis and multi-
organ failure. These figures clearly must be interpreted with
considerable caution, not least because of possible publica-
tion bias. However, it may be that the benefits of dantrolene
are restricted to patients with high peak temperatures (in the
40°C to 42°C range), whereas less importance may need to
be placed on reports of the efficacy of dantrolene in patients
with lower peak temperatures.
Serotonin syndrome, in contrast, is characterised by rapid
onset of markedly increased muscle tone amounting to
myoclonus, with shivering, tremor, and hyperreflexia. Contrac-
tion of opposed muscle groups tends to generate heat at a
greater rate than can be lost by vasodilatation and sweating,
leading to hyperpyrexia and cardiovascular instability. In
addition, the patient may have confusion and diarrhoea.
Mortality is reported as 10% to 15% [30]. Patients on
monoamine oxidase inhibitors and selective serotonin
reuptake inhibitors are at particular risk, and indeed care must
be taken with a multiplicity of drugs with similar properties
which are frequently used in anaesthesia and intensive care.
Management of severe cases is by immediate paralysis
accompanied by sedation and ventilation. This rapidly cuts off
excess heat production and enables the body to restore
thermal equilibrium. Milder cases can be managed with
expectant observation alone.
Hepatic and metabolic complications
MDMA is a significant cause of drug-induced liver failure,
accounting for up to 20% of all liver failure in patients under
25 years of age, possibly depending on local factors [31].
There are two distinct forms, one associated with hyper-
pyrexia and the other occurring in isolation. The former is
characterised by centrilobular necrosis and microvascular
steatosis (as in heatstroke), whereas the latter is most often
an acute cholestatic hepatitis with eosinophils and histiocytes
probably indicating a hypersensitivity reaction [32,33]. A
range of severity in both of these forms is noted clinically. The
presentation is that of acute hepatitis, sometimes progressing
to encephalopathy. Management is supportive. The promo-
tion of abstinence in these patients is important as recurrence
may occur on re-exposure to the drug.
Non-traumatic rhabdomyolysis is a complication common to
many illicit substances. Two main mechanisms are usually
responsible. The first is pressure necrosis of muscle in
unconscious patients, sometimes complicated by compart-
ment syndromes. The second is excessive muscle contrac-
tion leading to diffuse tissue disruption and consequent
myoglobin release. These effects are aggravated by a variety
of other derangements common in these patients, particularly
hyperthermia and hypokalaemia. Either of these mechanisms
may be further complicated by traumatic rhabdomyolysis,
which is also common due to the effects of the substances
taken, since they may cause aggression, impaired judgement,
risk-taking behaviour, and impaired coordination.
There is frequently muscle swelling and tenderness but there
may be no signs or symptoms. Even at an early stage, large
amounts of haemoglobin and myoglobin can be found in the
urine. Ultrasonagraphy can be of assistance in revealing
hyperechoic regions of pressure necrosis in the asympto-
matic patient. The diagnostic biochemical abnormality is a
tenfold rise in CK, although aspartate transferase, alanine
transferase, and lactate dehydrogenase are usually also
raised. Acute renal failure is the usual sequel. Hyperkalaemia
and hypocalcaemia can also occur.
Management consists of close monitoring of fluid and electro-
lyte status, with fluid replacement to produce an adequate
urine output. Alkalinisation of urine is recommended to
reduce the risk of myoglobinuric renal failure but may delay
excretion of amphetamines. Biochemical abnormalities should
Available online http://ccforum.com/content/12/1/202
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Table 2
Common toxidromes in illicit drug use
Toxidrome Features Drugs implicated
Adrenergic Hypertension, tachycardia, mydriasis, diaphoresis, agitation,  Amphetamines, cocaine, ephedrine, phencyclidine
dry mucus membranes
Sedative Stupor and coma, confusion, slurred speech, apnea Barbiturates, benzodiazepines, ethanol, opiates
Hallucinogenic Hallucinations, psychosis, panic, fever, hyperthermia Amphetamines, cannabinoids, cocaine
Narcotic Altered mental status, slow shallow breaths, miosis, bradycardia,  Opiates
hypotension, hypothermia, decreased bowel sounds
Epileptogenic Hyperthermia, hyperrreflexia, tremors, seizures Cocaine, phencyclidine
Adapted from [35].be closely monitored and managed appropriately. Caution
should be taken with calcium replacement as rebound hyper-
calcaemia may occur. Hyponatraemia, an important endocrine
and metabolic complication of MDMA use, is described above
in the section on neurological complications.
Polysubstance abuse, clinical diagnosis, and
the place of urine testing
It is important for the clinician to be aware of the common
toxidromes associated with illicit substance misuse as these
can lead to a rapid clinical diagnosis (Table 2). In some
cases, the diagnosis may be unclear. Since many drug
complications may be difficult to distinguish from other
medical conditions and since polysubstance use is common,
it is often helpful to have the result of a rapid near-patient
urine test to confirm clinical suspicion and guide
management decisions. However, these tests only confirm
the presence of a substance in urine, indicating consumption
of the drug during the previous 24 to 72 hours, but do not
give any indication of blood levels or of the relationship of the
drug to the clinical effects observed. If the patient’s mental
state appears disturbed, consent for the test can be
assumed. Interaction with alcohol must also be considered,
especially in cases of cocaine abuse. Alcohol causes hepatic
metabolism of cocaine to an ethyl homologue cocaethylene
that has a plasma half-life three to five times longer than that
(30 to 60 minutes) of cocaine [1]. Despite being a central
nervous system depressant, alcohol is taken with cocaine to
increase the desired effects of the latter, but it also increases
cocaine’s potential for toxicity. The risk of immediate death is
18 to 25 times greater for cocaine coingested with alcohol
than for cocaine alone [34].
Conclusion
Because drug use is widespread and increasing, every
medical practitioner needs to have a working understanding of
the basic pharmacology and acute medical implications of
illicit drugs. Emergencies may occur in an expected situation,
such as at a club or party, but sometimes the patient is unable
to give a coherent history and needs to be diagnosed from
physical signs and clinical suspicion. Apart from management
of the medical emergency, there is also an opportunity for the
use of brief interventions in order to prevent further drug use
by the patient; use of this ‘teachable moment’ has been shown
to be effective in other situations. We hope that this short
review will help to inform those who may encounter these
complications in the course of their work.
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